Ofev

Lungs
Biotech

PureTech's deupirfenidone shows durable effect in IPF study

PureTech presented results of an open-label extension study of itsidiopathic pulmonary fibrosis candidate deupirfenidone, showing its durability.
Kevin Dunleavy May 20, 2025 5:15pm
Bristol Myers Squibb

BMS charts 2nd pulmonary fibrosis win with LPA1 antagonist

Sep 11, 2023 10:05am